Bone Metastases and Bone Loss Medical Treatment in Prostate Cancer Patients
Prostate cancer is a malignancy in urology with the highest incidence metastasize to the bone up to 70%. The incidence of skeletal related event (SRE) by 46.1% such as severe pain, pathologic fractures, spinal compression syndrome and hypercalcemia, with a consequence of higher inpatient care and w...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Interna Publishing
2013-01-01
|
| Series: | Acta Medica Indonesiana |
| Online Access: | http://www.actamedindones.org/index.php/ijim/article/view/126 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Prostate cancer is a malignancy in urology with the highest incidence metastasize to the bone up to 70%. The incidence of skeletal related event (SRE) by 46.1% such as severe pain, pathologic fractures, spinal compression syndrome and hypercalcemia, with a consequence of higher inpatient care and worsen the patient’s prognosis.
Androgen deprivation therapy (ADT) as a metastatic prostate cancer treatment itself causes an osteopenia or osteoporosis.
Bisphosphonate inhibits normal and pathologic osteoclast-mediated bone resorption by several mechanisms. Denosumab is the latest treatment option in bone metastases. Multi-study shows the efficacy of denosumab is better than zoledronic acid for SRE prevention. Adverse events between denosumab and bisphosphonate are comparable.
Key words: prostate cancer, bone metastases, bone loss, treatment.
|
|---|---|
| ISSN: | 0125-9326 2338-2732 |